Fiasp (Insulin Aspart (Niacinamide)) Patent Expiration, LOE Window & CMS Spending

Fiasp (Insulin Aspart (Niacinamide)) by Novo Nordisk: Biologic BLA (Purple Book Regime), 0 AB generics, $73.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayB208751 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$73.3M
2024 Medicare Part D Spend$64.1M
2024 Medicaid Spend$9.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.